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Cimetidine improves the reliability of creatinine as a marker of
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Cimetidine improves the reliability of creatinine as a marker of
glomerular filtration. To investigate whether the administration of
cimetidine can improve the reliability of creatinine as a marker of GFR,
we compared the creatinine clearance (Cr) to the clearance of the true
filtration markers 51Cr-EDTA (CEDTA) and inulin (C1), after oral
ingestion of cimetidine in 10 healthy men and 29 patients with varying
degrees of renal dysfunction. After administration of cimetidine for
three to six days, serum creatinine level rose in all participants, while
CEDTA and C1, remained stable in a subgroup of 14 subjects in whom
they were measured before as well as after the administration of
cimetidine. The mean (± SD) ratios of Ccr to CEDTA (N = 39) and of Cr
to C1 (N = 19) after ingestion of cimetidine were 1.02 0.13 and 1.01
0.13, respectively, and did not differ significantly from unity. This
high degree of accuracy of the cimetidine-aided Ccr was present over
the entire range of renal function in the study population. Our results
also indicated an improved precision of the cimetidine-aided measure-
ment of Car, resulting in a variability that did not differ significantly
from that of the measurement of CEDTA or C1,,. We conclude that after
oral administration of cimetidine, the creatinine clearance can be used
as a reliable measure of GFR within a broad range of renal function.
In routine clinical practice, serum creatinine and creatinine
clearance are commonly used to assess renal function. How-
ever, the use of creatinine as a marker of the glomerular
filtration rate (GFR) has several pitfalls [1, 2]. The ratio of
creatinine clearance to GFR therefore exceeds unity and may
even rise above 2.0 in patients with severe renal insufficiency
[3]. Tubular secretion of creatinine is the major cause of
overestimation of the true GFR by the creatinine clearance [3,
4]. The contribution of tubular secretion to the overall renal
clearance of creatinine is unpredictable and variable. It has
been shown that tubular secretion increases as renal function
decreases [31, and that it may vary with time [5]. Therefore, no
fixed relationship between the creatinine clearance and GFR
exists, and the creatinine clearance is a rather unreliable marker
of GFR. Furthermore, the "adaptive" increase of tubular
secretion of creatinine when renal function deteriorates, pre-
vents serum creatinine to be used as a marker of early renal
dysfunction. Lastly, together with the variability of other
factors such as extrarenal excretion and creatinine generation,
the unpredictability of tubular secretion limits the use of the
reciprocal value of serum creatinine as marker of GFR in
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studies on the progression of renal disease [2]. To circumvent
these problems, GFR can be measured with the aid of "true
filtration markers" such as inulin, '251-iothalamate, 99mTc..
DTPA (diethylenetriaminepenta-acetic acid) or 51Cr-EDTA
(ethylenediaminetetra-acetic acid). The major disadvantages of
these techniques are their inconvenience and high cost in
comparison with measurement of the creatinine clearance.
Secretion of creatinine by the tubular transport system can be
inhibited by several anionic and cationic substances [1]. One of
these is the frequently used drug cimetidine, which has been
shown to reduce creatinine clearance without impairing GFR
[6—10]. Limiting the tubular secretion of creatinine by the
administration of cimetidine might thus improve the validity of
creatinine as a marker of GFR. To test this hypothesis, we
compared the clearances of creatinine to that of two true
filtration markers (51Cr-EDTA and inulin) after the administra-
tion of cimetidine in healthy persons and in patients with
varying degrees of renal dysfunction.
Methods
Selection of the participants
The study was performed in 10 healthy volunteers and in 29
patients with varying degree of renal dysfunction, who were
selected from our outpatient population. Their calculated
endogenous creatinine clearance (ECC) according to the for-
mula of Cockroft and Gault [11] had to exceed 20 mI/mm, as
measurement of the plasma clearance of 5tCr-EDTA is not
reliable when ECC falls below this value [12]. Other exclusion
criteria were: pregnancy, diabetes mellitus, use of H2-receptor
antagonists or antiacids, allergy for cimetidine, use of drugs of
which the metabolism can be influenced by cimetidine, use of
drugs which are known to interfere with creatinine secretion,
and unstable renal function. The study protocol was approved
by the Hospital Ethics Committee and informed consent was
obtained from all participants.
Study design
The 39 participants of the study visited the outpatient clinic
on two separate occasions. During the interval between both
study days they used oral cimetidine (Tagamet') in a dosage
described below. The principal measure of evaluation was the
ratio of the creatinine clearance (CrS) to the simultaneously
measured clearance Cr-EDTA (CEDTA) after administration
of cimetidine. In a subgroup of 19 participants the inulin
clearance (C1,,) was used as a second reference method. To
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investigate a possible effect of cimetidine on GFR, clearances of
51Cr-EDTA and of inulin were measured before as well as after
administration of cimetidine in a subgroup of 14 subjects. In
addition we studied in all participants the effect of cimetidine on
the validity of the 24-hour creatinine clearance (Cr24) and
1.5-hour creatinine clearance (Crl.S), as these methods are
more practical in ambulatory patients.
Clearance measurements
The above-mentioned clearance measurements, using the
standard clearance formula U,*V/P, for calculations, were
performed in the following way:
a.) Determination of 24-hour creatinine clearance (Cr24).
The 24 hour excretion of creatinine was obtained by the mean of
the creatinine excretions in the 24 hour urine, collected during
the last two days preceding each visit. Serum creatinine con-
centration was determined in the first drawn serum sample at
each visit (SCr).
b.) Determination of 1.5 -hour creatinine clearance (C-1.5).
Upon arrival in the outpatient clinic an oral water load of 10
mi/kg in one hour was given and the urine was collected during
90 minutes. The mean of the serum creatinine concentrations at
the beginning and end of this period was used for calculation of
the clearance.
c.) Simultaneous measurement of the clearance of creatinine
(CcrS), 51Cr-EDTA, and (in applicable cases) mu/in during
three consecutive half-hour intervals. Following the measure-
ment of the Ccrl.5 (see in b.), and after an equilibration period
of at least 75 minutes, CrS and C were determined during
three clearance periods of 30 minutes. Inulin (InutestR, Lae-
vosan GmbH) was administered as a continuous i.v. infusion
with priming and maintenance dose. Satisfactory urinary output
during this period was maintained by replacing urinary losses
by an oral load of tap water. The means of the serum concen-
trations of creatinine or inulin in blood samples at the beginning
and end of each period were used for clearance calculations.
Subsequently, the clearance values of the three half-hour peri-
ods were averaged and the mean was used for statistical
analysis. The 5tCr-EDTA clearance was derived from the
plasma disappearance curve of 51Cr-EDTA using plasma sam-
ples obtained at 150, 180, 210, and 240 minutes (points of time
bracketing the 3 clearance periods) after a single i.v. injection of
51Cr-EDTA [13, 14]. We used the formula described by
Bröchner-Mortensen and Rodbro to calculate the renal clear-
ance of 51Cr-EDTA [15]. The dose of 51Cr-EDTA was 100 pCi
if ECC exceeded 30 mllmin, and 50 pCi if ECC was less.
During the clearance measurements, the participants were in
a supine or sitting position. All measurements were carried out
between 9.00 a.m and 2.00 p.m. On the morning of both study
days a standard breakfast containing only two slices of bread
with jelly and two glasses of water were allowed before starting
the measurements to exclude a possible rise in creatinine by
dietary intake.
Apart from the clearance measurements, whole blood counts,
liver function tests, and analyses of the urinary sediment were
performed to monitor possible side-effects of cimetidine.
Laboratory methods
Serum and urine concentrations of creatinine were deter-
mined by an enzymatic method (Boehringer Mannheim GmbH),
Table 1. Daily dose and dosing scheme of cimetidine for different








>75 2000; 400-400-400-800 800
50—75 1600; 400-400-400-400 600
30—50 1400; 400-400-600 600
20—30 1200; 400-400-400 400
a ECC, endogenous creatinine clearance according to the Cockroft-
Gault equation [11]b The first dose was taken on waking up, the last dose at bedtime, and
inteijacent doses at regular intervals
Ingested at home before visit to the outpatient clinic
permitting accurate quantitation of the creatinine concentration
and eliminating measurement of spurious non-creatinine chro-
mogens, as occurs with the conventional alkaline picrate
method. Inulin concentrations were determined by a semi-
automated technique (centrifugal analysis, Multistat) using en-
zymatic degradation of inulin [16]. 51Cr-EDTA was measured in
plasma samples with a gamma counter (LKB Wallace). Other
measurements were performed according to standard labora-
tory techniques.
Dosage of cimetidine
To obtain maximal inhibition of tubular secretion of creati-
nine, we prescribed the maximally allowed oral daily dose of
2000 mg in case of normal renal function. As cimetidine is
cleared largely by the kidney, the dose was adjusted according
to the degree of renal dysfunction in an attempt to achieve
approximately equal blood cimetidine levels in all participants.
The prescribed doses for the different levels of renal function
are given in Table 1. Compliance was checked by pill counting.
Duration of cimetidine intake
After administration of cimetidine a rise in serum creatinine
concentration can be expected. In such a case a new steady
state, which is necessary to perform clearance studies, will be
reached after four elimination half-times (T112) of serum creat-
mine. The kinetics of creatinine are multi-compartmental, but it
has been demonstrated that the error arising from applying a
one-compartmental model is negligible [17]. In that case, the
turnover time (TEL) is equal to the quotient of the volume of
distribution (VD) and the clearance (C) of a substance which can
be defined as the sum of the renal and extrarenal clearance (CR
+ CNR):
TEL = VD/(CR + CNR).
Based on a D of creatinine of 0.5 x body weight [17—20] and an
extrarenal clearance of 0.04 liter/day/kg [211, TEL can be
expressed as a function of body weight (BW in kg) and
endogenous creatinine clearance (ECC in mi/mm):
TEL (in hours) = 500 x BW/(60 x ECC + 1.67 x BW).
Since T112 ln2 x TEL,
T112 (in hours) = 5.78 X BW/(ECC + 0,028 x BW).
Hilbrands et a!: Cimetidine and creatinine clearance 1173
Since daily measurements of creatinine were not feasible in this
outpatient population, we estimated the number of days (four
times T112) required to reach a steady state for any combination
of body weight and creatinine clearance using the above for-
mula. In every participant, 24-hour urine collection prior to the
second visit only started after the duration of cimetidine intake
had been long enough to attain the predicted new steady state.
The duration of cimetidine intake thus equalled the number of
days required to achieve steady state plus two days.
Statistical analysis
All values are expressed as means SD. For comparison of
the renal function parameters before and after the administra-
tion of cimetidine, Student's f-test and Wilcoxon's test for
paired observations were used when appropriate. Differences
from unity of the ratios between clearances measured by test
and by reference method, were analyzed by Student's f-test for
paired data. Differences between more than two subgroups
were evaluated by the Kruskal-Wallis test. Comparison of the
SDS of the C1-S to GFR ratios before and after administration,
and comparison of the variances of clearance values obtained
by different methods, were performed by analysis of the Pear-
son correlation coefficient between sum and difference of paired
data. A zero correlation coefficient means equal variances or
SDS. A P-value smaller than 0.05 was considered statistically
significant.
Results
Characteristics of the study population
The 10 healthy persons were all men with a median age of 24
years (range: 19 to 30). Their median calculated ECC was 111
ml/min/l.73 m2 (range: 92 to 141). The 29 persons (21 men, 8
women) with impaired renal function who participated in the
study had a median age of 48 years (range: 25 to 66) and a
median ECC of 51 ml/minll.73 m2 (range: 20 to 97). Five of
them had undergone unilateral nephrectomy to donate for
living-related kidney transplantation and four were renal al-
lograft recipients. The remaining patients had the following
renal disorders: chronic glomerulonephritis (10), chronic pyelo-
nephritis (4), polycystic kidney disease (2), bilateral renal artery
stenosis (1), status after malignant hypertension (1), partial
nephrectomy of single functioning kidney (1), and unknown (1).
The calculated duration of cimetidine intake required to achieve
steady state for serum creatinine varied from one to four days
with the following distribution: one day, N = 17; two days, N =
16; three days, N = 5; four days, N = 1. Since collection of two
24-hour urine samples was started after steady state was
supposed to be reached, cimetidine was administered during the
last three to six days preceding the second visit. For practical
reasons, the interval between the two clearance measurements
usually was longer than this latter period and varied from six to
fifteen days. The prescribed dosage of cimetidine was 2000
mg/day in 15 subjects, 1600 mg/day in 11 subjects, 1400 mg/day
in nine subjects, and 1200 mg in four cases. One of the
participants used 1000 mg of cimetidine per day instead of the
prescribed dosage of 1400 mg/day. Another participant had left
three tablets of 400 mg in excess, while it was not clear when he
had forgotten to ingest them. All participants were included for
evaluation of the results.
Table 2. Ratios between the creatinine clearance and the
simultaneously measured clearance of 51Cr-EDTA or inulin before
and after administration of cimetidine
Ratio before cimetidine Ratio after cimetidine
Cc-S/CEDTA 1.02 0.13 (0.98—1.06)(N = 39)
CCrS/CEDTA 1.19 0.13 (1.11—1.26) 1.01 011a,b (0.94—1.07)(N = 14)
CcrS/Cjn 1.01 0.13a (0.95—1 .07)(N = 19)
CcrS/Cin 1.23 0.20 (1.12—1.35) 0.96 008a,b (0.92—1.01)(N = 14)
CCrl.S/CEDTA 0.97 O.12 (0.93—1.01)(N = 39)
CCr24ICEDTA 0.85 0.16c (0.80—0.90)(N = 39)
Values are expressed as means SD (95% confidence interval).
Abbreviations are in the text.
a Not significant vs. unity
b p < 0.001 for comparison with pre-cimetidine value
P < 0.001 for difference from unity
Effects of cimetidine
Administration of cimetidine resulted in a clear-cut rise in
serum creatinine concentration in all participants. Mean S. (±
SD) increased from 144 77 j.tmol/liter to 176 94 molIliter,
the mean rise being 23 11% (P < 0.001). In agreement with
this observation we found a substantial fall in Cr24 from 74
36 to 59 30 mI/mm (P < 0.001) and in Crl.5 from 89 44 to
68 33 ml/min (P < 0.001). As expected, no statistically
significant effect of the administration of cimetidine on the
clearance of 51Cr-EDTA or inulin could be demonstrated.
CEDTA (N = 14) was 86 37 mI/mm before administration of
cimetidine and 82 34 mI/mm afterwards (NS). For C1 (N =
14), the corresponding values were 86 41 mI/mm and 88 40
mI/mm (NS).
By blocking tubular secretion of creatinine, cimetidine will
reduce the difference between the creatinine clearance and
GFR, measured by the clearance of a true filtration marker.
Consequently, the ratio of the creatinine clearance to GFR
should approximate 1.0. Table 2 gives an overview of the ratios
of CCr to the clearance of true filtration markers before and after
the administration of cimetidine. After the participants had used
cimetidine, their mean CrS to CEDTA was 1.02 0.13. This
value is not significantly different from unity, rendering the
cimetidine-aided measurement of the creatinine clearance an
accurate method of estimation of GFR. Using inulin as a second
marker of GFR, the finding of a CrS to C1,, ratio of 1.01 0.13
(NS vs. unity) pointed to a similar conclusion. In a subgroup of
participants (N = 14; median ECC = 86 ml/min/l .73 m) the
ratios of CrS to CEDTA and of CcrS to C1,, were obtained
before as well as after administration of cimetidine. Both ratios
showed a significant decrease after administration of cimetidine
(Table 2).
Next, we classified the 39 participants in three groups accord-
ing to their renal function (CEDTA < 40 ml/min/l .73 m2, CEDTA
40 to 80 ml/min/l.73 m2, CEDTA > 80 ml/min/l.73 m2). As
expected, absolute and relative rise of serum creatinine were
larger in the patients with more severe renal dysfunction (Table
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CEDTA ml/min/1.73 m2
<40 40—80 >80
N II 17 11
Absolute rise of S. jsmol/l 60 28 26 I ia 16 7
Relative rise of Sr % 26 14 23 l0 19 7
CCr-S/CDTA after 1.01 021b 1.01 007" 1.03 0.08"
cimetidine
N 5 6 8
CrSICin after cimetidine 1.08 0.18" 0.99 0.11" 0.97 0.10"
Values are expressed as means SD. Abbreviations are in the text.
a p < 0.001
b Not significant vs. unity and no significant differences for CEDTA
<40 vs. CTA 40—80, CEDTA <40 vs. CEDTA >80, and CEDTA 40—80 vs.
CEDTA >80
3). More notably, after administration of cimetidine, no signif-
icant differences in the CrS to CEDTA ratio nor in the CrS to
C1 ratio between the three subgroups were found (Table 3). In
addition, the mean CrS to CEDTA ratio after administration of
cimetidine of the 10 patients with primarily glomerular diseases
(1.03 0.14) did not differ significantly from that of the four
patients with primarily tubulointerstitial diseases (0.94 0.02).
The conclusion that CrS, after use of cimetidine, reflected
GFR over a broad range of renal function in the study popula-
tion is illustrated in Figure 1.
To test whether the use of cimetidine, besides improving the
accuracy, was also able to improve the precision of the creati-
nine clearance as a measure of GFR, we compared the SDS of
the ratios of CCF-S to CEDTA and of CCrS to C1, before
administration of cimetidine and the SDS of the same ratios after
administration of cimetidine in the subgroup of participants who
underwent these clearance measurements twice. The SD of the
CcrS to C1, ratio decreased markedly from 0.20 to 0.08 (P <
0.05), while the SD of the CCrS to CEDTA ratio did not change
significantly (0.13 vs. 0.11; NS). The precision of the cimeti-
dine-aided creatinine clearance was further evaluated by com-
paring the variability of the CrS with the variability of C1, and
CEDTA in the group of 19 subjects in whom all three measure-
ments were performed simultaneously. No significant differ-
ences could be demonstrated between the variances of C-S
and CEDTA (1321 vs. 1158) on the one hand or between the
variances of CcrS and C1, (1321 vs. 1560) on the other hand.
Since the measurement of the creatinine clearance as carried
out in our simultaneous study (CrS) may still be impractical,
we also tested the accuracy of Crl.S and Cr24 after admin-
istration of cimetidine, The mean Cr 1.5 to CEDTA ratio again
closely approximated 1.0 while the Cr24 to CEDTA ratio was
significantly less than unity (Table 2).
Adverse effects
Nine participants mentioned the following complaints during
use of cimetidine: dizziness (three cases; cimetidine dosage
2000 mg/day, 1600 mg/day, and 1400 mg/day), muscle weakness
(two cases; cimetidine dosage 1600 and 1200 mg/day), dyspep-
sia (two cases; cimetidine dosage 2000 and 1600 mg/day),
0 20 40 60 80 100 120
CED1-A, mI/min/1.73 m2
Fig. 1. Ratio of C,-S to CEOTA vs. clearance of 51Cr-EDTA after
administration of cimetidine.
diarrhea (one case; cimetidine dosage 1400 mg/day), and insom-
nia (one case; cimetidine dosage 1600 mg/day). All symptoms
resolved after stopping drug intake at the end of the study.
None of the participants had elevations of liver enzymes,
leucocytopenia or thrombocytopenia, or signs of interstitial
nephritis in their urinary sediments.
Discussion
The rise in serum creatinine and the fall in creatinine clear-
ance due to the inhibitory effect of cimetidine on renal tubular
secretion of creatinine have been regarded as impediments to
the routine clinical evaluation of renal function. Yet we tried to
make use of this action of cimetidine in order to improve the
validity of creatinine as a marker of GFR. The results of our
study suggest that this goal can be achieved. Use of cimetidine
in a dosage and duration which were adjusted to renal function
resulted in ratios of the creatinine clearance to the simulta-
neously measured clearance of 51Cr-EDTA and of inulin which
closely approximated unity.
For an adequate interpretation of the results, three important
questions have to be dealt with. First, does cimetidine have any
effect on GFR per se? In agreement with extensive data from
the literature [6—10, 22, 23] we could not demonstrate a signif-
icant effect of administration of cimetidine on GFR. Second,
does the finding of a ratio of creatinine clearance to GFR of
approximately 1.0 apply to all levels of renal function? Since
our study population was composed of individuals with a broad
range of renal function, the answer seems yes. Nevertheless,
deviations of the ratio from 1.0 in patients with different degrees
of renal dysfunction could theoretically have neutralized each
other. Analysis of the results after subdividing the participants
in three groups according to renal function, showed no signifi-
cant differences in the CrS to CEDTA and CrS to C1 ratio
between the three subgroups. Likewise we found no significant
difference between the mean CrS to CEDTA ratio of patients
with primarily glomerular disorders and of those with primarily
tubulointerstitial diseases, although the number of patients in
the latter group was too small to draw a firm conclusion. Since
patients with an endogenous creatinine clearance less than 20
ml/min were excluded from the study, no statement can be
Table 3. Effect of cimetidine on serum creatinine (S.), CcrS to
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made about the reliability of the cimetidine-aided creatinine
clearance in patients with more severe renal dysfunction. In the
third place, what is the magnitude of the variability of the ratio
of Cr to GFR? In other words, are the ratios of all individuals
lying within a narrow range? Administration of cimetidine
resulted in a decrease in the SD of the ratio of CrS to C1 and
thus appeared to improve the precision of the creatinine clear-
ance as a measure of GFR. The decrease in SD might even have
been larger if the concerning subgroup had consisted of patients
with more severe renal dysfunction, since the variability of C.
to GFR due to tubular secretion of creatinine rises with decreas-
ing renal function [3]. In that case, we also might have been able
to demonstrate a significant decrease in the SD of the ratio of
CcrS to CEDTA. We also compared the variance of the data
from measurement of CrS and the variances of the data from
simultaneous measurement of CEDTA and C1, respectively, in a
subgroup of 19 subjects. The variance of the data obtained by
any technique equals the variance in the study population plus
the variance introduced by the measuring error of that tech-
nique. Since the three different methods of clearance measure-
ment were performed in the same individuals, comparing the
variances comes to comparing the measuring errors. Thus if one
of these methods would be less precise, a larger variance of the
data from that particular method would be expected. From the
results it is clear that estimation of the GFR by measurement of
the cimetidine-aided creatinine clearance had about the same
extent of precision as measurement of the clearance of inulin or
of 51Cr-EDTA.
For daily clinical practice, it would be very helpful to have
available a reliable yet feasible method of estimation of GFR.
Our data indicate that after the administration of cimetidine the
easily performed Crl.S is a quite accurate measure of GFR as
determined by the clearance of 51Cr-EDTA. The underestima-
tion of this GFR value by Cr24 may partly be explained by
errors in the collection of 24 hour urine. In addition, from the
presence of a circadian rhythm for the GFR with higher values
during daytime [24], one might expect that GFR measured in
the late morning hours will be higher than the 24-hour creatinine
clearance. Finally, since creatinine clearance has been reported
to depend on urinary flow rate [25], lower urinary flow rates
during the night may have contributed to the underestimation of
GFR (in this case CEDTA) by Cr24.
No serious adverse effects of cimetidine were noted which is
of special importance for this situation where cimetidine is used
for a non-therapeutical purpose. The report of subjective com-
plaints by a number of participants could have been influenced
by the fact that, in accordance with ethical guidelines, informa-
tion about possible side-effects was provided. In a recent
meta-analysis of randomized clinical trials with cimetidine the
rate of adverse effects was found to be equal in cimetidine and
placebo groups even with dosages as high as 2000 mg/day [26].
Previous studies concerning the effects of cimetidine on renal
function reported mean ratios of creatinine clearance to GFR
after administration of cimetidine varying from 0.89 [8] to 1.35
[6]. Since the inhibition of tubular creatinine secretion is
thought to be a competitive process [22], the effect of cimetidine
on the ratio of the creatinine clearance to GFR would be
expected to vary with the blood concentration of cimetidine.
The variation in the reported results may thus be related to
differing dosage schedules and ways of administration of cimet-
idine. The fall of the mean creatinine clearance to GFR ratio
below 1.0 in some studies raises the question of whether tubular
reabsorption of creatinine might exist. In that case the mean
ratio of about 1.0 in our study could have been achieved by
incomplete inhibition of tubular secretion in part of the subjects
and domination of reabsorption of creatinine over more com-
plete inhibited secretion in others. Tubular reabsorption of
creatinine has been demonstrated in rats [271, but in humans
sufficient proof is still lacking.
Our study extends recent observations by Roubenoff et al,
who demonstrated improved accuracy and precision of the
creatinine clearance by use of oral cimetidine [28]. Their study
population consisted of 13 patients with lupus nephritis and
near normal renal function. The mean ratio of the creatinine
clearance to the GFR, simultaneously determined by measure-
ment of the clearance of DTPA, was reduced to 1.14 (compared
to a CrS to CEDTA ratio of 1.02 in our study). Somewhat
unexpectedly, serum creatinine did not rise in 4 of their 13
patients. The dosing scheme of cimetidine differed slightly from
ours with a lower total daily dose (1600 mg) and a lower
morning dose (400 mg) just before clearance measurements
were performed. Moreover, in all patients clearance studies
were performed within 48 hours after starting cimetidine intake,
whereas we estimated the number of days required to reach
steady state for each individual. Based on these calculations, all
but one of our participants was expected to be in steady state
after receiving cimetidine for 72 hours. We believe that future
studies, including daily measurements of creatinine, will be
needed to actually determine the time needed for a steady state
to be achieved after starting cimetidine.
It should be stressed that before use of the cimetidine-aided
creatinine clearance can be promoted as an exact measure of
GFR, the reproducibility of this technique has to be investi-
gated. Reproducibility of any method for determining GFR is
best established by temporally separated determinations in
individual subjects with stable renal function. If the reproduc-
ibility would prove to be high, there are many situations in
which measurement of the cimetidine-aided creatinine clear-
ance or serum creatinine concentration may furnish a useful
assessment of renal function. First, in certain instances it may
replace classical measurement of GFR with a true filtration
marker as the latter is more expensive and less convenient. As
such it can offer prospects in studies concerned with long-term
follow-up of renal function [29]. Moreover, monitoring of the
progress of renal deterioration by plotting the reciprocal values
of serum creatinine against time [30] might become more
reliable when serum samples are obtained after use of cimeti-
dine. Finally, administration of cimetidine might improve the
sensitivity of serum creatinine in detecting small degrees of
renal dysfunction by restoring the inverse relationship between
serum creatinine and GFR which is actually blunted by the
increase of tubular secretion with reduction of GFR [3].
In summary, oral administration of cimetidine improved the
reliability of the creatinine clearance as a measure of the
glomerular filtration rate. The ratio of the cimetidine-aided
creatinine clearance to GFR approximated unity over a broad
range of renal function. Moreover, the variability of the method
was comparable to that of standard methods. For daily practical
use the cimetidine-aided 1.5-hour creatinine clearance seems a
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valuable test of renal function. Studies investigating the repro-
ducibility of the cimetidine-aided creatinine clearance are re-
quired.
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